← Every company
AstraZeneca PLC Patents
What AstraZeneca PLC has filed at the patent office — applications as well as grants, because a filing is on the record eighteen months before anyone has to say what it was for.
AZN on carbonthat →Filings on file
53
Granted
0
Still pending
53
Filed under
7 names
53 filings
Newest filing first. A pending application has no patent number yet, and most never get one.
| Invention | Patent |
|---|---|
| POLQ INHIBITORSA61K 31/52, C07D 473/26, C07D 473/30, A61P 35/02, A61P 35/00, A61K 31/4178, A61K 31/496, C07D 235/18, C07D 401/06, C07D 471/04Filed as ASTRAZENECA AB2026-05-11Bernard BARLAAM | pending |
| Graph Construction and Visualization of Multiplex Immunofluorescence ImagesG06V 20/69, G06T 11/23, G06T 7/62, G16H 50/20, G06V 20/695, G06V 10/82, G06F 18/29, G06F 3/04817, G06T2207/10064Filed as AstraZeneca AB2026-04-24Khan Richard Baykaner | pending |
| CRYSTAL FORM OF BAXDROSTAT, AND PREPARATION METHOD THEREFOR AND USE THEREOFA61K 31/4725, C07D 401/04, A61P 9/12, A61P 13/12, C07B2200/13Filed as AstraZeneca Ireland Limited2026-03-26Xiaoting ZHAI | pending |
| FUSED PYRIMIDINE COMPOUNDS AS KCC2 MODULATORSA61P 25/08, C07D 471/04, C07D 487/04, A61P 25/22, A61P 25/00, A61P 29/00, A61K 31/519, A61K 31/5377, A61K 31/541, A61K 31/553, C07D 491/04, C07D 491/048, C07D 498/10, C07D 519/00Filed as Astrazeneca AB2026-03-02Rebecca Elizabeth Jarvis | pending |
| MOLECULAR SWITCHESC07K 14/78, A61K 31/4985, C12N 9/506, C12N 15/86Filed as ASTRAZENECA AB2025-12-22Natalie Jo TIGUE | pending |
| LILRB2 BINDING PROTEINS AND USES THEREOFC07K 16/2803, A61P 35/00, A61K2239/55, A61K 40/42, A61K 40/31, A61K 40/11, A61K 35/17, A61K 38/00, C07K2317/52, C07K2317/565, C07K2317/71, C07K2317/76, C07K2317/92, C07K2317/94, C12N 15/63Filed as ASTRAZENECA AB2025-12-15Des C. JONES | pending |
| BILIARY TRACT CANCER TREATMENT WITH ANTI-CLAUDIN 18.2 ADCA61K 47/6863, A61K 47/68031, A61K 47/6889, A61K 47/6851, A61K 47/6849, A61P 35/00, G01N 33/5759, A61K2039/505, A61K2039/545, C07K 16/28, C07K2317/565, C07K2317/73, C07K2317/76, G01N2800/50, G01N2800/52Filed as ASTRAZENECA AB2025-12-09Alejandra NEGRO | pending |
| ARMORED T CELLSA61K 35/17, C12N2310/20, A61P 35/00, A61K 40/31, A61K 40/50, A61K 40/11, C12N 9/222, A61K 9/0019, C07K 14/525, C07K 14/70503, C12N 5/0638, C12N 15/113, C12N2510/00Filed as ASTRAZENECA AB2025-12-05Maria Letizia GIARDINO TORCHIA | pending |
| PYRROLOPYRIMIDINE CARBOXAMIDESC07D 487/04, A61P 35/00, A61K 31/519Filed as ASTRAZENECA AB2025-12-01Avipsa GHOSH | pending |
| PHARMACEUTICAL COMPOSITIONSA61K 9/2054, A61K 9/2009, A61K 9/2013, A61K 9/2813, A61K 9/2826, A61K 9/284, A61K 9/2866, A61K 31/519Filed as ASTRAZENECA AB2025-11-25Farhan Abdel Karim Mohammad AL HUSBAN | pending |
| METHODS, COMPOSITIONS, AND COMBINATIONS FOR THE TREATMENT OF OVARIAN CANCERA61K 39/3955, A61P 35/00, A61K 31/282, A61K 31/337, A61K 31/502, C07K 16/22, C07K 16/2827Filed as ASTRAZENECA AB2025-11-24Tsveta Petrova MILENKOVA-ILIEVA | pending |
| TREATMENT OF LUPUSC07K 16/2866, A61P 37/02, A61K2039/505, A61K2039/545, C07K2317/21, C07K2317/565, C07K2317/71, C07K2317/76Filed as ASTRAZENECA AB2025-11-18Raj TUMMALA | pending |
| METHODS AND COMBINATIONS FOR TREATING CERVICAL CANCERC07K 16/2827, A61P 35/00, A61K 31/282, A61K2039/505, C07K 16/2818, C07K2317/31, C07K2317/76Filed as ASTRAZENECA AB2025-11-13Geoffrey KIM | pending |
| METHODS OF TREATMENT OF CHRONIC KIDNEY DISEASEC12N 15/113, A61P 13/12, A61K 31/7115, A61K 31/712, C12N2310/11, C12N2310/3231, C12N2310/3341, C12N2310/341Filed as ASTRAZENECA AB2025-11-10Lisa BUVALL | pending |
| SARS-COV-2 ANTIBODIES AND METHODS OF USING THE SAMEA61P 31/14, C07K 16/104, A61K2039/505, C07K2317/33, C07K2317/76, C07K2317/92, G01N 33/56983, G01N2333/165Filed as ASTRAZENECA UK LIMITED2025-11-05Taylor COHEN | pending |
| COMBINATION OF CAPIVASERTIB, A CDK4/6 INHIBITOR AND FULVESTRANT FOR USE IN THE TREATMENT OF BREAST CANCERA61K 31/506, A61K 31/519, A61P 35/00, A61K 31/565, A61K 31/567, A61K 45/06, A61K2300/00Filed as AstraZeneca AB2025-11-04Simon BARRY | pending |
| CONJUGATES COMPRISING CLEAVABLE LINKERSA61K 47/68037, A61K 47/6889, A61K 47/6855, A61P 35/00Filed as ASTRAZENECA AB2025-10-17Akbar Husain KHAN | pending |
| CONJUGATES COMPRISING CLEAVABLE LINKERSA61K 47/6889, A61K 47/6855, A61K 47/68037, A61K 47/6851, A61K 47/6883, A61K 47/545, A61K 47/549, A61K 47/60, A61K 47/6849, A61P 35/00, C07H 15/203Filed as ASTRAZENECA AB2025-10-17Akbar Husain KHAN | pending |
| METHODS OF TREATING HEART FAILURE WITH PRESERVED EJECTION FRACTION EMPLOYING DAPAGLIFLOZIN AND COMPOSITIONS COMPRISING THE SAMEA61K 31/70, A61K 31/7034, A61P 9/04, A61K 9/20, A61K 31/155, A61K 31/403, A61K 45/06, A61K2300/00Filed as AstraZeneca AB2025-10-17Anna Maria LANGKILDE | pending |
| PHARMACEUTICAL FORMULATIONSA61K 9/2054, A61K 31/4745, A61K 9/2009, A61K 9/2013, A61K 9/2027, A61K 9/2059, A61K 9/2077, A61K 9/2095, A61K 9/284, A61K 9/2866, A61K 9/4808, A61K 9/485, A61K 9/4858, A61K 9/4866Filed as AstraZeneca AB2025-10-15Farhan Abdel Karim Mohammad Al Husban | pending |
| COMBINATION OF A PARP1 INHIBITOR AND A SELECTIVE ESTROGEN DEGRADER FOR TREATING CANCERA61K 31/4745, A61K 31/496, A61P 35/00, A61K 31/444, A61K 31/519, A61K 31/565, A61K 45/06, A61K2300/00Filed as ASTRAZENECA AB2025-10-10Mark Robert ALBERTELLA | pending |
| TREATMENT OF NON-SMALL CELL LUNG CANCERA61K 31/337, A61K 39/3955, C07K 16/2827, A61P 35/00, A61K 33/243, A61K 31/282, A61K 31/519, A61K 31/555, A61K 31/7068, A61K 45/06, A61K2039/505, A61K2039/545, A61K2300/00, C07K2317/21, C07K2317/76Filed as ASTRAZENECA AB2025-10-09Norah SHIRE | pending |
| COMBINATION OF ZIBOTENTAN AND DAPAGLIFLOZIN FOR THE TREATMENT OF CHRONIC KIDNEY DISEASE AND LIVER FIBROSISA61K 31/497, A61K 31/7034, A61P 1/16, A61P 3/06, A61P 3/10, A61P 13/12, A61K 31/70, A61K2300/00Filed as AstraZeneca AB2025-10-08Philip Ambery | pending |
| FLUIDIC MIXER UNIT DEVICE FOR NANOPARTICLE PRODUCTIONB01F 33/30, B01F 33/3017, B33Y 80/00, B01F 25/4331, B01F 33/824, B01F 33/813, B01F 25/102, B01F 25/4332, B01F2101/22, A61K 9/513, A61K 9/5192, B01L 3/502784, B01L 3/5085, B01L2200/021, B01L2200/12, B01L2300/0867Filed as AstraZeneca AB2025-10-03Audrey GALLUD | pending |
| METHOD OF TREATMENT WITH MPO INHIBITORSFiled as ASTRAZENECA AB2025-10-03Erick MICHAËLSSON | pending |
| JAK1 SELECTIVE INHIBITORSA61P 37/00, A61K 9/0075, C07D 403/04, C07D 403/14, A61P 17/14, A61P 3/10, A61K 31/506Filed as AstraZeneca AB2025-09-30KARL MAGNUS NILSSON | pending |
| COMBINATIONS OF KRAS INHIBITOR AND ATR INHIBITOR FOR THE TREATMENT OF CANCERA61P 35/00, A61K 31/519, A61K 31/553, A61K 31/5377, A61K 45/06, A61K2300/00Filed as ASTRAZENECA AB2025-09-30Alexander KOERS | pending |
| SUBSTITUTED INDAZOLES AS IRAK4 INHIBITORSC07D 487/04, A61P 37/00, A61P 17/06, A61P 11/06, A61P 37/06, A61P 17/00, A61P 35/02, A61P 37/08, A61P 11/00, A61P 29/00, A61P 35/00, A61K 31/5025, A61K 31/519Filed as AstraZeneca AB2025-09-29Ina TERSTIEGE | pending |
| Use of Inhibitors to Increase Efficiency of CRISPR/Cas InsertionsC12N 15/907, C12Q 1/6804, C12N2310/20, C12N 9/226, C07D 487/04, C07D 519/00, C07K 14/7051, C12N 5/0636, C12N 5/0696, C12N 9/99, C12N 15/111, C12N 15/86, C12N 15/88, C12N2510/00, C12N2710/10043, C12N2740/10043, C12N2740/15043, C12N2750/14143, C12Q2527/127Filed as ASTRAZENECA AB2025-09-26Marcello MARESCA | pending |
| COMPOUNDS AND THEIR USE IN TREATING CANCERA61P 35/00, C07D 401/14, C07D 413/14, A61K 47/55, A61K 31/4545, A61K 31/496, A61K 31/497, A61K 31/501, A61K 31/506, A61K 31/513, A61K 31/5377, C07D 471/04, C07D 487/04Filed as ASTRAZENECA AB2025-08-29Peter ASTLES | pending |
| PHARMACEUTICAL FORMULATION COMPRISING HETERODIMERIC RELAXIN FUSION PROTEINS AND USES THEREOFA61K 38/2221, C07K 14/64, A61P 9/00, A61K 47/10, A61K 47/12, A61K 47/183, A61K 47/22, A61K 47/26, C07K2319/30, C07K2319/31Filed as ASTRAZENECA AB2025-08-26Peng KE | pending |
| CERTAIN (2S)-N-[(1S)-1-CYANO-2-PHENYLETHYL]-1,4-OXAZEPANE-2-CARBOXAMIDES AS DIPEPTIDYL PEPTIDASE 1 INHIBITORSC07D 267/10, C07D 413/14, A61P 43/00, A61P 11/06, A61P 31/12, A61P 11/08, A61P 37/08, A61P 11/00, A61P 11/14, A61P 31/06, A61P 31/16, A61P 35/00, A61K 31/553, A61K 45/06, C07D 413/12, C07D 417/12Filed as AstraZeneca AB2025-08-26Hans Roland LÖNN | pending |
| CHEMICAL COMPOUNDSC07D 401/12, A61P 35/00, A61K 31/498Filed as ASTRAZENECA AB2025-08-12JEFFREY WALLACE JOHANNES | pending |
| PRMT5 INHIBITOR FOR USE IN CANCER THERAPYFiled as ASTRAZENECA AB2025-08-12James Thomas LYNCH | pending |
| COMBINATION OF ZIBOTENTAN AND DAPAGLIFLOZIN FOR THE TREATMENT OF ENDOTHELIN RELATED DISEASESA61K 31/497, A61P 13/12, A61K 31/351, A61K 31/70, A61K 31/7034, A61K2300/00Filed as AstraZeneca AB2025-08-11Peter GREASLEY | pending |
| NUCLEIC ACIDS ENCODING BCL2-ASSOCIATED ATHANOGENE 3 (BAG3) FOR GENE THERAPYFiled as ASTRAZENECA IRELAND LIMITED2025-08-11Nicolas CHRISTOFOROU | pending |
| Methods, Combinations, and Uses for the Treatment of Muscle Invasive Bladder CancerA61P 35/00, C07K 16/2827, A61K 33/243, A61K 31/555, A61K 31/7068, A61K 38/00, A61K 39/395, A61K 45/06, A61K2039/505, A61K2039/545, C07K2317/524, C07K2317/71, C07K2317/76, A61K2300/00Filed as AstraZeneca AB2025-06-24Ashok Gupta | pending |
| COMBINATION OF ZIBOTENTAN AND DAPAGLIFLOZIN FOR THE TREATMENT OF CHRONIC KIDNEY DISEASE AND LIVER FIBROSISFiled as AstraZeneca AB2025-06-23Philip Ambery | pending |
| Dosage Regimen for the Treatment of CancerA61K 31/444, A61K 31/4745, A61K 45/06, A61P 15/14, A61P 35/00, A61K 9/20, A61K 31/436, A61K 31/506, A61K 31/519, A61K2300/00Filed as AstraZeneca AB2025-06-17Pablo MORENTIN GUTIERREZ | pending |
| ANTI-IL5R ANTIBODY FORMULATIONSA61K 39/39591, A61P 11/06, A61P 37/08, A61P 11/00, A61P 1/04, A61P 11/14, A61K 9/0019, A61K 9/08, A61K 9/19, A61K 47/10, A61K 47/12, A61K 47/14, A61K 47/183, A61K 47/22, A61K 47/26, A61K 47/34, A61K2039/505, C07K 16/2866Filed as ASTRAZENECA AB2025-06-16SABA GHAZVINI | pending |
| COMBINATION OF ANTIBODY-DRUG CONJUGATES AND DNMT INHIBITORSA61K 47/6851, A61K 47/6849, A61K 47/6889, A61K 47/65, A61P 35/00, A61K 47/68037, A61K 31/706, A61K 31/7068, C07K 16/30, C07K2317/565, A61K2300/00Filed as AstraZeneca UK Limited2025-05-29Daisuke OKAJIMA | pending |
| CANCER THERAPY WITH CAPIVASERTIB AND FULVESTRANTA61K 31/519, A61P 35/00, A61K 31/565, A61K 31/59, A61K2300/00Filed as AstraZeneca AB2025-05-29Simon BARRY | pending |
| ARGINASE INHIBITORS AND METHODS OF USE THEREOFC07F 5/025, A61P 11/00, A61P 29/00, A61P 35/00, A61K 31/69Filed as ASTRAZENECA AB2025-05-23Scott Nathan MLYNARSKI | pending |
| THERAPEUTIC COMBINATIONS OF CAPIVASERTIB AND VENETOCLAXA61K 31/519, A61P 35/00, A61K 31/635, A61K2300/00Filed as AstraZeneca AB2025-05-07Simon Thomas BARRY | pending |
| COMBINATION THERAPIES FOR THE TREATMENT OF CANCERA61K 31/519, A61P 35/00, A61K 31/436, A61K 31/4439, A61K 31/444, A61K 31/565Filed as ASTRAZENECA AB2025-05-07Simon Thomas BARRY | pending |
| Anti-CTLA Antibody Compositions and Related MethodsC07K 16/2818, A61P 35/00, A61K 9/0019, A61K 47/183, A61K 47/22, A61K 47/26, A61K2039/505, C07K2317/21, C07K2317/40, C07K2317/53, C07K2317/565, C07K2317/76, C07K2317/92, C07K2317/94Filed as Astrazeneca AB2025-05-01Xia LUO | pending |
| ORAL FORMULATION OF N-PYRIDINYL ACETAMIDE DERIVATIVE FOR TREATING INTERSTITIAL LUNG DISEASEA61K 31/497, A61K 9/0053, A61K 9/10, A61K 9/2009, A61K 9/2013, A61K 9/2054, A61K 9/2813, A61K 9/2853, A61K 9/2866, A61K 47/38Filed as AstraZeneca AB2025-04-25Håkan Wikström | pending |
| RECOMBINANT APYRASE PROTEIN FOR USE IN THE TREATMENT OF AN ISCHEMIC EVENT AT A DOSE OF 40-240 MGA61K 38/46, A61P 9/10, A61K 9/0019, A61K 31/4365, A61K 31/519, A61K 31/616, A61K 31/7064, A61K 31/7076, C12Y 306/01005, A61K2300/00Filed as ASTRAZENECA AB2025-04-24Ann-Charlotte Eva EGNELL | pending |
| AMIDO HETEROAROMATIC COMPOUNDSC07D 413/06, A61P 1/16, A61K 31/422, A61K 31/4245, A61K 31/5377, C07D 261/18, C07D 271/06, C07D 333/38, C07D 409/06, C07D 413/04, C07D 413/12, C07D 413/14, C07D 417/06, C07D 471/04, C07D 471/08, C07D 487/04, C07D 491/10, C07D 491/107, C07D 493/10, C07D 498/10Filed as AstraZeneca AB2025-04-15Daniel Tor PETTERSEN | pending |
| ORAL FORMULATION OF A THERAPEUTIC COMPOUNDA61K 9/2054, A61K 31/4725, A61K 9/1617, A61K 9/1652, A61K 9/1694, A61K 9/2013, A61K 31/4709Filed as ASTRAZENECA AB2025-04-11Cecilia Gunnarsson | pending |
| COMBINATIONS OF A SERD FOR THE TREATMENT OF CANCERA61K 31/4745, A61K 31/5377, A61P 35/04, A61P 35/00, A61K 31/138, A61K 31/4196, A61K 31/436, A61K 31/437, A61K 31/4535, A61K 31/506, A61K 31/517, A61K 31/519, A61K 31/565, A61K 31/568, A61K 45/06, A61K2300/00Filed as AstraZeneca AB2025-04-10Larissa DE SOUZA CARNEVALLI | pending |
| PERFUSION BIOREACTOR TANGENTIAL FLOW FILTRATIONC12M 33/14, B01D2311/2523, B01D 61/18, B01D 63/02, B01D 63/082, B01D2311/2665, B01D2313/243, B01D2315/10, C12M 29/04, C12M 29/10, C12M 29/18, C12M 47/10Filed as ASTRAZENECA AB2025-04-08Jimmy VU | pending |
| EGFR TKIs FOR USE IN THE TREATMENT OF NON-SMALL LUNG CANCERA61K 31/506, A61P 35/00, A61K 31/4155, A61K 31/444, A61K 31/517, A61K 31/519Filed as ASTRAZENECA AB2025-04-07Yuri RUKAZENKOV | pending |
Filings are matched to the company by applicant name, so a subsidiary filing under its own name is only here if that name resolves to this company. The applicant is printed as filed, which makes a wrong match visible. A patent is not a product: most applications are never granted, and most grants are never built.
More on AZN
Company overviewEverything on AZN in one place, with the price.SEC filingsWhat AZN's 8-Ks say happened: results, departures, auditor changes.Insider tradingWhat AZN's own officers and directors buy and sell.LobbyingWhat AZN spends lobbying Congress, and on what.Who lobbies for itThe lobbyists on AZN's account, and who they worked for.Federal contractsWhat federal agencies pay AZN.Workplace safetyWhat OSHA found at AZN's sites.